XML 138 R69.htm IDEA: XBRL DOCUMENT
v3.23.1

Significant transactions (Details) € in Millions, shares in Millions |  |  |  |  |  |  | 1 Months Ended | 12 Months Ended |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 17, 2022 USD ($) | Dec. 22, 2021 USD ($) | Oct. 08, 2021 USD ($) | Jan. 31, 2020 USD ($) | Jan. 31, 2020 EUR (€) | Jan. 06, 2020 USD ($) | Nov. 23, 2019 USD ($) | Mar. 31, 2020 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2021 USD ($) shares | Dec. 31, 2020 USD ($) | Dec. 31, 2022 SFr / shares | Feb. 10, 2021 | Jan. 31, 2020 EUR (€) | Sep. 06, 2018 USD ($)
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) |  |  |  |  |  |  |  |  | $ 1,077,000,000 | $ 735,000,000 | $ 10,173,000,000 |  |  |  |
Par value per share | SFr / shares |  |  |  |  |  |  |  |  |  |  |  | SFr 0.50 |  |  |
Deferred tax liability (asset) |  |  |  |  |  |  |  |  | (1,053,000,000) | (673,000,000) | (792,000,000) |  |  |  |
Intangible assets other than goodwill |  |  |  |  |  |  |  |  | 31,644,000,000 | 34,182,000,000 |  |  |  |  |
Revenue from sale of goods |  |  |  |  |  |  |  |  | 50,545,000,000 | 51,626,000,000 | 48,659,000,000 |  |  |  |
Borrowings |  |  |  |  |  |  |  |  | 22,485,000,000 | 25,523,000,000 |  |  |  |  |
Depreciation, property, plant and equipment |  |  |  |  |  |  |  |  | 1,163,000,000 | 1,208,000,000 |  |  |  |  |
Innovative Medicines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from sale of goods |  |  |  |  |  |  |  |  | 42,121,000,000 | 42,790,000,000 | 39,805,000,000 |  |  |  |
Sandoz |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from sale of goods |  |  |  |  |  |  |  |  | 9,454,000,000 | 9,811,000,000 | 9,835,000,000 |  |  |  |
Corporate |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from sale of goods |  |  |  |  |  |  |  |  | $ (1,030,000,000) | (975,000,000) | $ (981,000,000) |  |  |  |
Roche Holding AG, Switzerland |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations |  |  |  |  |  |  |  |  |  | $ 20,700,000,000 |  |  |  |  |
Number of bearer shares | shares |  |  |  |  |  |  |  |  |  | 53.3 |  |  |  |  |
Gain on divestment of interests in associated companies |  |  |  |  |  |  |  |  |  | $ 14,556,000,000 |  |  |  |  |
Sandoz | Sandoz |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred, divestment-date fair value |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 800,000,000
Depreciation, property, plant and equipment |  |  |  |  |  |  |  | $ 38,000,000 |  |  |  |  |  |  |
Amortisation, intangible assets other than goodwill |  |  |  |  |  |  |  | 102,000,000 |  |  |  |  |  |  |
Impairment loss recognised in profit or loss, intangible assets and goodwill |  |  |  |  |  |  |  | $ (42,000,000) |  |  |  |  |  |  |
Aspen Global Incorporated | Sandoz |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred, acquisition-date fair value |  |  |  | $ 324,000,000 |  |  |  |  |  |  |  |  |  | € 294.0 |
Portion of consideration paid consisting of cash and cash equivalents upfront payment |  |  |  | (303,000,000) | € (274.0) |  |  |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) |  |  |  | 238,000,000 |  |  |  |  |  |  |  |  |  |  |
Additional recognition, goodwill |  |  |  | 86,000,000 |  |  |  |  |  |  |  |  |  |  |
Other net assets |  |  |  | 26,000,000 |  |  |  |  |  |  |  |  |  |  |
Deferred tax liability (asset) |  |  |  | 16,000,000 |  |  |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  |  | 196,000,000 |  |  |  |  |  |  |  |  |  |  |
Potential milestone maximum payments |  |  |  | 77,000,000 | 70.0 |  |  |  |  |  |  |  |  |  |
Customary purchase price adjustment |  |  |  | 30,000,000 | € 27.0 |  |  |  |  |  |  |  |  |  |
Cash transferred |  |  |  | 273,000,000 |  |  |  |  |  |  |  |  |  | 247.0 |
Contingent consideration recognised as of acquisition date |  |  |  | $ 51,000,000 |  |  |  |  |  |  |  |  |  | € 47.0 |
The Medicines Company | Innovative Medicines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred, acquisition-date fair value |  |  |  |  |  | $ 9,600,000,000 |  |  |  |  |  |  |  |  |
Portion of consideration paid (received) consisting of cash and cash equivalents |  |  |  |  |  |  | $ (9,600,000,000) |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) |  |  |  |  |  | 7,100,000,000 |  |  |  |  |  |  |  |  |
Additional recognition, goodwill |  |  |  |  |  | 2,500,000,000 |  |  |  |  |  |  |  |  |
Cash offer per ordinary share |  |  |  |  |  |  | $ 85 |  |  |  |  |  |  |  |
Deferred tax liability (asset) |  |  |  |  |  | 1,400,000,000 |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  |  |  |  | $ 8,500,000,000 |  |  |  |  |  |  |  |  |
GlaxoSmithKline plc (GSK) | Sandoz |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred, acquisition-date fair value |  |  | $ 415,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Portion of consideration paid consisting of cash and cash equivalents upfront payment |  |  | (350,000,000) |  |  |  |  |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) |  |  | 308,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Additional recognition, goodwill |  |  | 107,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Deferred tax liability (asset) |  |  | 16,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill |  |  | 292,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Number of brands in portfolio to acquire |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |
Number of markets for the acquired brands |  |  |  |  |  |  |  |  |  |  |  |  | 100 |  |
Potential milestone maximum payments |  |  | 150,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Cash transferred |  |  | 351,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration recognised as of acquisition date |  |  | $ 64,000,000 |  |  |  |  |  |  |  |  |  |  |  |
Gyroscope Therapeutics Holdings plc. | Innovative Medicines |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred, acquisition-date fair value | $ 1,000,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Portion of consideration paid consisting of cash and cash equivalents upfront payment | (800,000,000) | $ (800,000,000) |  |  |  |  |  |  |  |  |  |  |  |  |
Identifiable assets acquired (liabilities assumed) | 900,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional recognition, goodwill | 100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred tax liability (asset) | 200,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets other than goodwill | 1,100,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone maximum payments |  | $ 700,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration recognised as of acquisition date | $ 200,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Subsidiaries [member] | The Medicines Company |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Disclosure of detailed information about business combination [line items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proportion of ownership interest in subsidiary |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |

X
- Definition The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2022-03-24 -Paragraph B64 -Subparagraph f -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B -URIDate 2022-03-24 + Details
Name: | ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of additional goodwill recognised, except goodwill included in a disposal group that, on acquisition, meets the criteria to be classified as held for sale in accordance with IFRS 5. [Refer: Goodwill; Disposal groups classified as held for sale [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2022-03-24 -Paragraph B67 -Subparagraph d -Clause ii -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d_ii&doctype=Appendix&subtype=B -URIDate 2022-03-24 + Details
Name: | ifrs-full_AdditionalRecognitionGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2022-03-24 -Paragraph 118 -Subparagraph e -Clause vi -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vi&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of outstanding funds that the entity is obligated to repay. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_Borrowings
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2022-03-24 -Paragraph B64 -Subparagraph f -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B -URIDate 2022-03-24 + Details
Name: | ifrs-full_CashTransferred
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount, at acquisition date, of contingent consideration arrangements recognised as consideration transferred in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2022-03-24 -Paragraph B64 -Subparagraph g -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_g_i&doctype=Appendix&subtype=B -URIDate 2022-03-24 + Details
Name: | ifrs-full_ContingentConsiderationRecognisedAsOfAcquisitionDate
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 12 -IssueDate 2022-03-24 -Paragraph 81 -Subparagraph g -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_DeferredTaxLiabilityAsset
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 16 -IssueDate 2022-03-24 -Paragraph 73 -Subparagraph e -Clause vii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_vii&doctype=Standard -URIDate 2022-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 16 -IssueDate 2022-03-24 -Paragraph 75 -Subparagraph a -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_a&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_DepreciationPropertyPlantAndEquipment
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfBusinessCombinationsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 3 -IssueDate 2022-03-24 -Paragraph B64 -Subparagraph i -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B -URIDate 2022-03-24 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Name IFRS -Number 3 -IssueDate 2022-03-24 -Paragraph IE72 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_IE72&doctype=Illustrative%20Examples -URIDate 2022-03-24 + Details
Name: | ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of impairment loss recognised in profit or loss for intangible assets and goodwill. [Refer: Impairment loss recognised in profit or loss; Intangible assets and goodwill] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 38 -IssueDate 2022-03-24 -Paragraph 118 -Subparagraph e -Clause iv -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_iv&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_ImpairmentLossRecognisedInProfitOrLossIntangibleAssetsAndGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2022-03-24 -Paragraph 118 -Subparagraph e -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard -URIDate 2022-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 54 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_IntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The nominal value per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 79 -Subparagraph a -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_ParValuePerShare
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The portion of consideration paid or received, consisting of cash and cash equivalents, in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]; Cash and cash equivalents; Consideration paid (received)] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 7 -IssueDate 2022-03-24 -Paragraph 40 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_40_b&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalents
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow from the disposal of non-current assets or disposal groups classified as held for sale and discontinued operations. [Refer: Discontinued operations [member]; Disposal groups classified as held for sale [member]; Non-current assets or disposal groups classified as held for sale] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 7 -IssueDate 2022-03-24 -Paragraph 16 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_ProceedsFromDisposalOfNoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleAndDiscontinuedOperations
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2022-03-24 -Paragraph 17 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2022-03-24 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2022-03-24 -Paragraph 16 -Subparagraph b -Clause iii -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2022-03-24 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2022-03-24 -Paragraph 19B -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_19B_c&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of revenue arising from the sale of goods. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 112 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_RevenueFromSaleOfGoods
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This expresses the amount of cash Novartis paid to the owners of AAA per ordinary share. + References No definition available. + Details
Name: | nvs_CashOfferPerOrdinaryShare
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_CustomaryPurchasePriceAdjustment
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_DivestmentDateFairValueOfTotalConsiderationTransferred
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_GainOnDivestmentOfInterestsInAssociatedCompanies
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_NumberOfBearerShares
Namespace Prefix: | nvs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_NumberOfBrandsInPortfolioToAcquire
Namespace Prefix: | nvs_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_NumberOfMarketsForTheAcquiredBrands
Namespace Prefix: | nvs_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_OtherNetAssets
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | nvs_PortionOfConsiderationPaidReceivedConsistingOfCashAndCashEquivalentsUpfrontPayment
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_PotentialMilestoneMaximumPayments
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_InnovativeMedicinesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_SandozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_CorporateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_RocheHoldingAGMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=nvs_SandozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nvs_AspenGlobalIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nvs_TheMedicinesCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nvs_GlaxoSmithKlinePlcGSKMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nvs_GyroscopeTherapeuticsHoldingsPlcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=ifrs-full_SubsidiariesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |